Skip to content
Screener

Xencor XNCR Net Income

Net Income at other companies

Amgen logo
AmgenAMGN
$2.38B+65.9%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$1.3B-6.8%
Janux Therapeutics logo
Janux TherapeuticsJANX
-$21.97M+35.1%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
-$55.43M-59.6%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-$52.88M-34.5%
Immix Biopharma, Inc. logo
Immix Biopharma, Inc.IMMX
-$10.09M-122%

Other financials

Income statement

See full
Revenue$51.2M+17.5%
Operating income-$37.1M-11.7%
Net income-$21.7M+29.5%
EPS (diluted)-$0.29+29.3%

Balance sheet

See full
Cash & equivalents$44.7M+0.5%
Total debt$170.1M-20.1%
Total equity$503.2M-18.9%
Total assets$725.0M-17.6%

Cash flow

See full
Operating cash flow-$55.7M-53.0%
CapEx$538.0K+40.5%
Free cash flow-$56.2M-52.9%

Valuation

See full
Market cap$1.6B+221%
Enterprise value$1.73B+159%
P/S15.3×+11.9×

Profitability

See full
Operating margin-205.8%-2,501pp
Net margin-155.6%+78.8pp
FCF margin-198.4%-1,485pp

Returns & leverage

See full
Return on equity-29.1%+0.2pp
Debt / equity0.3×0.0×
Current ratio6.4×+1.1×

Where this comes from

Reported directly by Xencor in its filing.

Tagged under the XBRL concept us-gaap:ProfitLoss.

The source filing: Xencor’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:02 PM EDT
Fiscal quarter
Q4 FY2028
Calendar quarter
Q4 2028
Accession
0001326732-26-000056
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Total other income (expense)15,1492,097(35,625)(2,985)
Loss before income tax expense (benefit) and noncontrolling interest(21,919)(31,075)(150,555)(79,340)
Income tax (benefit) expense(190)(250)90117
Net loss including noncontrolling interest(21,729)(30,825)(150,645)(79,457)
Net loss attributable to noncontrolling interest(214)
Net loss attributable to Xencor, Inc.$(21,729)$(30,825)$(150,645)$(79,243)
Net loss per share attributable to Xencor, Inc. (basic and diluted)$(0.29)$(0.41)$(1.99)$(1.07)
Weighted-average shares used in calculating net loss per share (basic and diluted)75,85974,27975,55573,975

Item 1. Financial Statements

FAQ

What is Xencor's net income?
Xencor (XNCR) reported net income of -$21.73M in Q2 2026.
How has Xencor's net income changed year-over-year?
Xencor's net income increased by 29.5% year-over-year, from -$30.83M to -$21.73M.
What is the long-term trend for Xencor's net income?
Over 4 years (2021 to 2025), Xencor's net income has grown at a 2.8% compound annual growth rate (CAGR), from $82.63M to -$92.14M.
What does net income mean?
Net income as the starting point for the indirect method operating cash flow reconciliation.

Ask your AI about Xencor's net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude